Cyrus Vaziri

This paper identifies CD73 as a regulator that limits oncogenic activity of mutant β-catenin in endometrial carcinomas, showing that its loss increases transcriptional activity and tumor progression.

This study identifies REV7 as a novel binding partner of ATRIP that inhibits ATR kinase activity and negatively regulates ATR signaling.

This study shows Rad18 suppresses 4NQO-induced oral carcinogenesis but not KrasG12D-driven lung tumors, highlighting context-specific tumor-suppressive roles.

This study identifies RNF25's role in protecting DNA replication forks from degradation, independent of its ubiquitin signaling functions.

This study identifies TRIP13 as a key factor protecting KRAS-mutant pancreatic cancer cells from DNA replication stress and therapy-induced damage.

This study identifies MAPK14/p38α as critical for HGEC spheroid growth, shaping its transcriptomic, proteomic, and metabolomic landscapes and promoting tumorigenic properties.

The paper shows that AR inhibition in prostate cancer causes DNA replication stress, which can be exploited by combining with a TLS inhibitor to enhance treatment efficacy.

This study characterizes DDR and CTA transcriptional landscapes in endometrial cancer subtypes, identifies aggressive subtypes, and reveals therapeutic vulnerabilities.

This study identifies RAD18's role in TMZ resistance and hypermutation in GBM by linking it to TLS and MMR pathways through CRISPR screening and mutation analysis.